Total Voting Rights
Updated : 10:00
4 April 2019
Cello Health plc
Total Voting Rights
As at 4 April 2019, Cello's issued share capital comprises 105,202,071 ordinary shares of 10 pence each ("Ordinary Shares"), of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company is therefore 104,749,071 Ordinary Shares.
The above figure (104,749,071 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Cello Health plc | 020 7812 8460 |
Mark Scott, Chief Executive | |
Mark Bentley, Group Finance Director
| |
Cenkos Securities plc | 020 7397 8900 |
Mark Connelly | |
Harry Hargreaves | |
Buchanan Mark Court | 020 7466 5000 |
Jamie Hooper | |
Sophie Wills | |
|
About Cello Health plc
Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.
Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.
Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit: https://cellohealthplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.